



Universiteit
Leiden
The Netherlands

Acromegaly : treatment and follow-up : the Leiden studies

Biermasz, N.R.

Citation

Biermasz, N. R. (2005, November 2). *Acromegaly : treatment and follow-up : the Leiden studies*. Retrieved from <https://hdl.handle.net/1887/4334>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4334>

Note: To cite this publication please use the final published version (if applicable).

CONTENTS

Introduction

1. General introduction 9
- Outline of the thesis 21

Treatment outcome in acromegaly

2. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. 27
J Clin Endocrinol Metab 2000; 85:4596-4602
3. Long-term follow-up results of postoperative radiotherapy in 36 patients with 43
acromegaly. *J Clin Endocrinol Metab 2000; 85:2476-2482*
4. Radiotherapy is effective in reducing serum growth hormone concentration to 59
safe levels. *Clin Endocrinol (Oxf) 2000; 53:321-327*
5. Direct postoperative and follow-up results of transsphenoidal surgery in 19 71
acromegalic patients pretreated with octreotide compared to those in untreated
controls. *J Clin Endocrinol Metab 1999; 84:3551-3555*
6. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses 83
growth hormone secretion as effectively as a 4-week interval.
Clin Endocrinol (Oxf) 2003; 58:288-295

Clinical outcome in acromegaly

7. Determinants of survival in treated acromegaly in a single center: 97
predictive value of serial insulin-like growth factor I measurements.
J Clin Endocrinol Metab. 2004; 89:2789-2796
8. Decreased quality of life in patients with acromegaly despite long-term cure of 113
growth hormone excess. *J Clin Endocrinol Metab. 2004; 89:5369-5376*
9. Morbidity after long-term remission for acromegaly: persisting joint-related 131
complaints cause reduced quality of life. *J Clin Endocrinol Metab 2005; 90:2731-2739*
10. Long-term maintenance of the anabolic effects of growth hormone (GH) on the 153
skeleton in cured patients with acromegaly. *Eur J Endocrinol 2005; 152: 53-60*

Dynamic tests in acromegaly

11. Intravenous octreotide test predicts the long-term outcome of 167
treatment with octreotide-long-acting repeatable in active acromegaly.
Growth Horm IGF Res. 2005; 15:200-206
12. Postoperative persistent thyrotropin releasing hormone (TRH)-induced 181
growth hormone release predicts recurrences in patients with acromegaly.
Clin Endocrinol (Oxf) 2002; 56:313-319

GH regulation during treatment and in rare cases of acromegaly

13. Octreotide represses secretory-burst mass and non-pulsatile secretion, but does not restore event frequency or orderly GH secretion in acromegaly. 193

Am J Physiol Endocrinol Metab 2004; 286:E25-30

14. Acromegaly caused by growth hormone releasing hormone (GHRH)-producing tumors: Long-term observational studies in three patients. *Submitted* 207

Current pharmacotherapy

15. Current Pharmacotherapy for acromegaly: a review. 229

Exp Opin Pharmacother, 2005, in press

Summary and Discussion

16. General Discussion and Conclusions 253

17. Summary, Nederlandse samenvatting 279

List of abbreviations 287

Nawoord 289

Curriculum Vitae 291

Publications 293